Revia Naltrexone is used in the treatment of alcohol dependence (with the consent of the patient and in combination with psychotherapeutic and social means) to prevent the pharmacological effects of exogenous opioids to maintain a pure state of opioids in patients with opioid dependence after detoxification previously conducted (as part of the psychological and vocational rehabilitation) .

Mode of action is blocking the opiate receptors. Competitively blocks the binding of agonists or replaces them with opiate receptors. Reduces or eliminates the symptoms caused by intravenous administration of opioids. Has the greatest affinity for mu- and kappa-receptors. It is effective when taken orally, is absorbed in the gastrointestinal tract by 96%.

Long-term appointment does not cause tolerance and dependence. Combination with high doses of opioids leads to an increased release of histamine with a typical clinical picture (facial flushing, itching, rash). In patients with opioid withdrawal cause seizures. In alcoholism associated with opioid receptors and blocks the effects of endorphins. Reduces the consumption of alcohol and prevents relapse within 6 months after the 12-week course of therapy (treatment success depends on the consent of the patient, and its interaction with the doctor).

Active substance is Revia Naltrexone Hydrochloride.